{"id":"https://openalex.org/W2003118947","doi":"https://doi.org/10.1016/0731-7085(96)01813-4","title":"Development and validation of a reversed-phase liquid chromatographic method for analysis of aspirin and warfarin in a combination tablet formulation","display_name":"Development and validation of a reversed-phase liquid chromatographic method for analysis of aspirin and warfarin in a combination tablet formulation","publication_year":1996,"publication_date":"1996-10-01","ids":{"openalex":"https://openalex.org/W2003118947","doi":"https://doi.org/10.1016/0731-7085(96)01813-4","mag":"2003118947","pmid":"https://pubmed.ncbi.nlm.nih.gov/8895078"},"language":"en","primary_location":{"id":"doi:10.1016/0731-7085(96)01813-4","doi":"https://doi.org/10.1016/0731-7085(96)01813-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0731-7085(96)01813-4","pdf_url":null,"source":{"id":"https://openalex.org/S174893293","display_name":"Journal of Pharmaceutical and Biomedical Analysis","issn_l":"0731-7085","issn":["0731-7085","1873-264X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical and Biomedical Analysis","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016161405","display_name":"Eda Ross Montgomery","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eda Ross Montgomery","raw_affiliation_strings":["DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0353, USA","Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0353, USA","institution_ids":["https://openalex.org/I1316910977"]},{"raw_affiliation_string":"Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Suzanne Taylor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suzanne Taylor","raw_affiliation_strings":["Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111978909","display_name":"James P. Segretario","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Segretario","raw_affiliation_strings":["Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Elizabeth Engler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Engler","raw_affiliation_strings":["Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034614095","display_name":"Dolores S. Sebastian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dolores Sebastian","raw_affiliation_strings":["Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research and Development, The DuPont Merck Pharmaceutical Company, Experimental Station, P.O. Box 80353, Wilmington, DE 19880-0353, USA","institution_ids":["https://openalex.org/I1316910977"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1316910977"],"apc_list":{"value":3680,"currency":"USD","value_usd":3680},"apc_paid":null,"fwci":1.3022,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":{"value":0.73086692,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"15","issue":"1","first_page":"73","last_page":"82"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10908","display_name":"Analytical Chemistry and Chromatography","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aspirin","display_name":"aspirin","score":0.996999979019165},{"id":"https://openalex.org/keywords/warfarin","display_name":"warfarin","score":0.9890000224113464},{"id":"https://openalex.org/keywords/combination-tablets","display_name":"combination tablets","score":0.4880000054836273},{"id":"https://openalex.org/keywords/stability-indicating-method","display_name":"stability-indicating assay","score":0.8709999918937683},{"id":"https://openalex.org/keywords/reversed-phase-liquid-chromatography","display_name":"reversed-phase liquid chromatography","score":0.8939999938011169},{"id":"https://openalex.org/keywords/simultaneous-determination","display_name":"simultaneous determination","score":0.6830000281333923},{"id":"https://openalex.org/keywords/method-validation","display_name":"method validation","score":0.7400000095367432},{"id":"https://openalex.org/keywords/drug-quantification","display_name":"pharmaceutical analysis","score":0.3230000138282776}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8937298655509949},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.7919548153877258},{"id":"https://openalex.org/C2909255381","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin Sodium","level":4,"score":0.7125528454780579},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.6889119148254395},{"id":"https://openalex.org/C2777628954","wikidata":"https://www.wikidata.org/wiki/Q18216","display_name":"Aspirin","level":2,"score":0.5411157011985779},{"id":"https://openalex.org/C77170095","wikidata":"https://www.wikidata.org/wiki/Q1753188","display_name":"Linearity","level":2,"score":0.4331624507904053},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.0},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000894","descriptor_name":"Anti-Inflammatory Agents, Non-Steroidal","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D001241","descriptor_name":"Aspirin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D001241","descriptor_name":"Aspirin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D002853","descriptor_name":"Chromatography, Liquid","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004355","descriptor_name":"Drug Stability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014859","descriptor_name":"Warfarin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D014859","descriptor_name":"Warfarin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D015203","descriptor_name":"Reproducibility of Results","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/0731-7085(96)01813-4","doi":"https://doi.org/10.1016/0731-7085(96)01813-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0731-7085(96)01813-4","pdf_url":null,"source":{"id":"https://openalex.org/S174893293","display_name":"Journal of Pharmaceutical and Biomedical Analysis","issn_l":"0731-7085","issn":["0731-7085","1873-264X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical and Biomedical Analysis","raw_type":"journal-article"},{"id":"pmid:8895078","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8895078","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of pharmaceutical and biomedical analysis","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.5683000087738037,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W130887233","https://openalex.org/W1965749655","https://openalex.org/W2071543850","https://openalex.org/W2076566145","https://openalex.org/W2080539682"],"related_works":["https://openalex.org/W2766849038","https://openalex.org/W2913642792","https://openalex.org/W4240185987","https://openalex.org/W2945601595","https://openalex.org/W2590814267","https://openalex.org/W7221365086","https://openalex.org/W4403955803","https://openalex.org/W2002802820","https://openalex.org/W2518955210","https://openalex.org/W2105724456"],"abstract_inverted_index":null,"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}